AOP 208
Alternative Names: AOP-208; LB-208Latest Information Update: 16 Jun 2026
At a glance
- Originator Leukos Biotech
- Developer AOP Orphan Pharmaceuticals AG; Leukos Biotech
- Class Antineoplastics
- Mechanism of Action Serotonin 1B receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 01 Jun 2026 Phase-I/II clinical trials in Acute myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in Spain, Austria (PO) (EUCT2025-523396-38-00)
- 01 Jun 2026 Phase-I/II clinical trials in Myelodysplastic syndromes (Late-stage disease, Second-line therapy or greater) in Spain, Austria (PO) (EUCT2025-523396-38-00)
- 15 Apr 2026 Aop Orphan Pharmaceuticals plans a phase I/II trial in Acute myeloid leukemia and Myelodysplastic syndrome (Second-line therapy or greater) in Spain (PO) in May 2026 (CTIS2025-523396-38-00)